1. Introduction {#sec1}
===============

Optical coherence tomography (OCT) is an optical imaging technique, which was introduced in the early 1990's. OCT has since become one of the most important imaging and diagnosis tools in ophthalmology.[@r1] The use of OCT or optical coherence microscopy (OCM) also expanded into a wide range of application fields such as neuro-, skin, and endoscopic imaging.[@r2][@r3]^--^[@r4] In neuroimaging, OCT has been utilized to investigate diseases such as Alzheimer's disease (AD),[@r5][@r6]^--^[@r7] Parkinson's disease,[@r8]^,^[@r9] and a variety of brain tumors.[@r10][@r11]^--^[@r12] However, in comparison to histology, OCT often lacks tissue-specific contrast of anatomical structures since conventional OCT image contrast is mainly based on light scattering. Current research in the OCT community has therefore also focused on validating and/or combining OCT with other established imaging modalities. One promising possibility is to combine OCT and fluorescence imaging (FI).[@r13]

FI provides tissue specificity based on biochemical or metabolic contrast through either autofluorescence or exogenous fluorescent dyes.[@r14] A combination of OCT and FI may enable the assessment of tissue morphology by OCM imaging with complementary biochemical tissue information retrieved by FI. Multimodal OCT and FI approaches have been implemented in different ways by research groups over the past years.[@r15][@r16][@r17][@r18][@r19][@r20][@r21][@r22][@r23][@r24][@r25][@r26][@r27][@r28][@r29][@r30][@r31][@r32][@r33][@r34]^--^[@r35] However, most presented OCM/fluorescence systems thus far have been based on rather complex optical layouts, which were designed to only work for one specific fluorescent dye and often relied on two separate light sources and paths, one for OCM and one for FI. Also, most of the OCT subsystems were operated in the near-infrared wavelength region and were designed for imaging the retina. Recently, using supercontinuum lasers working in the visible light spectrum, submicrometer axial resolutions for imaging the eye,[@r34]^,^[@r36][@r37]^--^[@r38] cells,[@r39] and brain tissue[@r5][@r6]^--^[@r7] were achieved.[@r40]

AD is characterized by the degeneration of neurons, the formation of extracellular plaques composed of amyloid-beta protein, and the accumulation of intracellular neurofibrillary tangles composed of tau protein.[@r41] In our recent work, we investigated neuritic amyloid-beta plaques in AD brain tissue using a high-resolution visible light OCM setup.[@r6]^,^[@r7] In histology, which is the gold standard for confirming these structures in neuropathology, amyloid-beta plaques can be identified using various stains, such as Congo red or immunohistochemical staining against amyloid-beta.[@r42]^,^[@r43] Another possibility to visualize amyloid-beta plaques is the use of fluorescent dyes, such as thioflavin-S or curcumin.[@r44][@r45]^--^[@r46] Curcumin is a yellow pigment, which is extracted from the rhizome of the plant *Curcuma longa* and has been used to label amyloid-beta deposits *ex-vivo*.[@r47]

Optical imaging plays a crucial role during dissections of brain tumors. In state-of-the-art neurosurgery, the surgeon utilizes an intraoperative microscope to navigate through the procedure and to localize malignant tissue areas to be resected.[@r48] The most common and most aggressive primary brain tumor is the glioblastoma multiforme, which belongs to a group of tumors called gliomas. Even with the best possible treatment, in most cases median survival does not exceed 15 months. Surgery followed by radiotherapy and concomitant temozolomide chemotherapy is the most important current treatment approach.[@r49] To enable maximal safe resections, intraoperative differentiation of tumor tissue and brain parenchyma is of utmost importance.[@r50] Recently, 5-aminolevulinic acid (5-ALA) FI has emerged as a powerful intraoperative modality capable of detecting high-grade glioma. The patient orally intakes the 5-ALA tracer prior to surgery. 5-ALA is then metabolized in the tumor cells to the fluorescent molecule protoporphyrin IX (PPIX).[@r51] During the operation, a blue light source, integrated in the neurosurgical microscope, is used to excite the fluorophore, making it easier for the surgeon to identify the malignant areas.[@r52][@r53]^--^[@r54] However, FI lacks morphological information about the tissue. It was already shown that OCT is a promising technique to investigate tumorous brain tissue.[@r12]^,^[@r55][@r56][@r57][@r58]^--^[@r59] Kut et al.[@r12] evaluated the attenuation coefficient extracted from the OCT data to distinguish between healthy tissue and tumors at different stages. Researchers have focused on integrating OCT into surgical microscopes.[@r60][@r61]^--^[@r62]

In this work, we present an adaptable, multimodal visible light OCM and FI setup. Our system is based on a supercontinuum laser operating in the visible wavelength range as a single, shared light source for both OCM and FI. By using a visible spectrum and appropriate spectral filter sets, the presented setup is able to excite various fluorescence dyes. In the OCM channel, the broad spectrum provides a high axial resolution to investigate microscopic features in the tissue. We present imaging of amyloid-beta plaques, in *ex-vivo* brain tissue of a mouse model of AD, using curcumin-based fluorescence contrast and visualize the three-dimensional structure of the brain tissue using the OCM channel of our multimodal setup. Finally, we investigate *ex-vivo* tumor biopsies with our multimodal setup. We identify the malignant regions with the FI setup and assess the morphological information of the brain parenchyma with the OCM. Finally, we evaluate the attenuation coefficients retrieved from the OCM measurements and perform a comparison to histology.

2. Methods {#sec2}
==========

2.1. Combined Visible Light Optical Coherence Microscopy and Fluorescence Imaging Setup {#sec2.1}
---------------------------------------------------------------------------------------

A multimodal visible light optical coherence microscope (OCM) and FI setup was developed. The OCM subsystem was first introduced in 2017.[@r6] A sketch of the setup is shown in [Fig. 1(a)](#f1){ref-type="fig"}.

![The multimodal FI and visible light OCM setup. (a) Sketch of the visible light OCM subsystem. (b) The FI subsystem after flipping the mirrors into the beam (indicated as F.M. in red). Components: collimator (Col.), dichroic mirror (D.M.), emission filter (Em.F.), excitation filter (Ex.F.), flip mirror (F.M.), pinhole (Pin.), and PMT (photomultiplier tube). (c) Photograph of a part of the interferometer of the OCM, where the yellow line indicates the laser beam of the OCM part and the blue dashed line the beam of the FI part. (d)--(f) A phantom of dragon-green microbeads was imaged. (d) OCM en-face projection and a representative B-scan. (e) FI image with a zoom-in. (f) Overlay of the OCM (red) and FI (green) images.](JBO-024-066010-g001){#f1}

The system is based on a free-space Michelson interferometer and a custom-built spectrometer. A supercontinuum laser in combination with a variable filter box (NKT Photonics SuperK EXTREME EXU-6 and VARIA) provided a broad visible spectrum (400 to 700 nm). An axial resolution of $0.88\text{  }\mu m$ in brain tissue was measured assuming a refractive index of 1.36.[@r63] A $20 \times$ magnification objective lens was utilized (Olympus, UPLFLN 20XP) leading to a measured transversal resolution of $2\text{  }\mu m$ and a theoretical depth of focus of $44\text{  }\mu m$. The A-scan rate of the system was 30 kHz. To switch from OCM to FI, two flipping mirrors (F.M.), see [Fig. 1(b)](#f1){ref-type="fig"}, were used to deflect the beam. A zoom-in photograph of the combined setup in [Fig. 1(c)](#f1){ref-type="fig"} shows the part where the two mirrors can be flipped. For FI, a variable combination of excitation filter (Ex.F.), dichroic mirror (D.M.), and emission filter (Em.F.) can be chosen and inserted in a filter cube (Olympus U-MF2) and may therefore enable flexible imaging of a variety of fluorophores. The light beam first passed through an excitation filter (Thorlabs MF 434-17, central wavelength = 434 nm, bandwidth = 17 nm) and was reflected by a dichroic filter (Thorlabs MD 434) and scanned across the sample. The beam in the sample arm was raster scanned using a microelectromechanical mirror scanner (MEMS, Mirrorcle Technologies, Inc.). The line scan camera (Basler spL8192-70km) in the spectrometer, the MEMS and the PMT were synchronized using a custom-made LabView \[Version 15.0 (64-bit)\] program. The photons emitted by sample fluorescence passed through an emission filter (Curcumin: Thorlabs MF 530-43, central wavelength = 530 nm, bandwidth = 43 nm; 5-ALA: MF 630-69, central wavelength = 630 nm, bandwidth = 69 nm). The fluorescent signal was focused by a lens onto a photomultiplier tube (Thorlabs, PMMT02, PMT), whose voltage output was digitized using a data acquisition card (National Instruments PCIe-6321). A pinhole with a diameter of $700\text{  }\mu m$ was placed in the focal plane before the PMT to reduce of out-of-focus light. For OCM imaging, the power at the sample was measured to be 0.8 mW and for FI 0.2 mW.

2.2. Tissue Preparation {#sec2.2}
-----------------------

### 2.2.1. Phantom imaging {#sec2.2.1}

To validate the setup, three fluorescence phantoms were imaged. For the first phantom, mounting medium (Aqua-Poly/Mount, Polysciences) was mixed (concentration 10%) with a curcumin powder (Sigma-Aldrich). This mixture was stuck onto paper and a region including both paper and curcumin was imaged. As a control case, only mounting medium on paper was imaged. Second, to verify the system's 5-ALA imaging capabilities, a fluorescence reference target (Starna Scientific, Protoporphyrin IX in PMMA, concentration 20%) was utilized (data not shown). For the third phantom dragon-green micro-beads (polystyrene-based microspheres dyed with dragon-green fluorophore) were imaged, and the results are shown in [Figs. 1(d)](#f1){ref-type="fig"}-[1(e)](#f1){ref-type="fig"}. [Figure 1(d)](#f1){ref-type="fig"} shows the OCM en-face image averaged over $10\text{  }\mu m$ in depth as well as a representative B-scan. [Figure 1(e)](#f1){ref-type="fig"} shows the corresponding FI image including a zoom-in. [Figure 1(f)](#f1){ref-type="fig"} shows an overlay of the OCM (red) en-face projection and the FI image (green).

### 2.2.2. Curcumin-stained mouse brain tissue {#sec2.2.2}

Heterozygous breeding of an AD mouse model, APPswe, PSEN1dE9 (APP-PS1, MMRRC stock number 34829, The Jackson Laboratory[@r64][@r65]^--^[@r66]) was established. Animal experiments were approved by the local ethics committee and by the Austrian Federal Ministry of Education, Science and Research under protocol BMWFW-66.009/0279-WF/V/3b/2018. One mouse was sacrificed at the age of 63 weeks. The brain was carefully removed and for one hemisphere a vibratome (Vibratome Series 1000 Sectioning System, The Vibratome Company) was used to cut $100\text{-}\mu m$-thick brain sections. The slices were cleared for 15 min following the SWITCH clearing protocol,[@r6]^,^[@r67] stained with curcumin, and imaged using a laser scanning microscope (Confocal Microscope LSM 700 Zeiss). The other hemisphere was embedded in paraffin and $3\text{  }\mu m$ thick slices were stained with curcumin and imaged by a conventional Olympus fluorescence microscope (BX51). Amyloid-beta plaques in consecutive sections were then visualized by immunohistochemical \[anti-A $\beta$ antibody (clone 6F/3D, diluted 1:100, Dako)\] staining for neuropathological confirmation of findings.

### 2.2.3. Tumor and control human brain samples {#sec2.2.3}

Brain tumor samples were retrieved intraoperatively. The surgeon used a surgical fluorescence microscope to identify 5-ALA-positive areas and resected the tumor-associated tissue. During tumor resection, 5-ALA-positive and/or -negative tissue samples were routinely collected. Half of the biopsy samples was directly processed for routine neuropathological work-up and the other half was imaged with the multimodal setup (Ethical approval EK 419/2008 - Amendment 04/2018). The fluorescence images were acquired before the OCM volumes to prevent photo bleaching. After OCM and FI, the samples were prepared for histology. Hematoxylin and eosin staining was performed and micrographs were acquired with a slide scanner (Hamamatsu NanoZoomer 2.0 HT). In total, 12 biopsies of 6 patients (age range 47 to 65 years) diagnosed with brain tumors were investigated. According to the surgeon six samples showed strong 5-ALA-positive fluorescence, three samples showed vague 5-ALA-positive fluorescence and three samples were 5-ALA negative. A detailed description of all biopsies can be found in [Table 1](#t001){ref-type="table"}.

###### 

The detailed information of the 12 biopsies of 6 patients. The 5-ALA status and the definite diagnosis of patient records are shown. 5-ALA − corresponds to no fluorescence, 5-ALA + to vague, and ++ to strong 5-ALA fluorescence.

  Patient ID   Biopsy ($n$)   Fluorescence status   Definite diagnosis
  ------------ -------------- --------------------- ------------------------------------------------
  I            1              5-ALA −               Adjacent brain parenchyma
  I            2              5-ALA ++              Compact tumor and infiltration zone
  II           3              5-ALA ++              Compact tumor and infiltration zone
  II           4              5-ALA ++              Diffuse tumor infiltration and necrotic tissue
  III          5              5-ALA ++              Infiltration zone
  IV           6              5-ALA −               Adjacent brain parenchyma
  V            7              5-ALA +               Physiological tissue and infiltration zone
  V            8              5-ALA +               Physiological tissue and infiltration zone
  V            9              5-ALA ++              Compact metastatic tissue
  VI           10             5-ALA −               Adjacent brain parenchyma
  VI           11             5-ALA −               Adjacent brain parenchyma
  VI           12             5-ALA ++              Compact tumor and infiltration zone

2.3. Data Acquisition and Postprocessing {#sec2.3}
----------------------------------------

Processed OCM volumes consisted of $4096(z) \times 500(x) \times 500(y)$ pixels and the fluorescence images comprised $500(x) \times 500(y)\text{  pixels}$. The field of view was $200 \times 200\text{  }{\mu m}^{2}$. Data were acquired using a custom made Labview program (LabView 2015, Version 15.0, 64-bit, National Instruments). The OCM data were processed following the steps described by Lichtenegger et al.,[@r7] and en-face projections were generated by averaging intensity over various depths. Fiji was used to generate composition images of FI and OCM results.[@r68]

### 2.3.1. Data processing of the brain biopsy measurements {#sec2.3.1}

An overview over the data processing pipeline for the tumor samples is shown in [Fig. 2](#f2){ref-type="fig"}. After FI \[[Fig. 2(1)](#f2){ref-type="fig"}\] and OCM \[[Fig. 2(3)](#f2){ref-type="fig"}\] acquisition, surface flattening was performed, and attenuation maps \[[Fig. 2(4)](#f2){ref-type="fig"}\] were generated following previous work.[@r6]^,^[@r12]^,^[@r69] A region of interest consisting of 100 B-scans was chosen manually and for each B-scan, the average attenuation coefficient was calculated \[[Fig. 2(5)](#f2){ref-type="fig"}\]. The respective average fluorescence signal \[[Fig. 2(2)](#f2){ref-type="fig"}\] was calculated to create a scatter plot \[[Fig. 2(6)](#f2){ref-type="fig"}\]. The fluorescence data \[${data}_{FI}(n),n = 1\ldots N,(N = 12\text{  biopsies})$\] was normalized using ${norm}_{FI}(n) = \frac{{data}_{FI}(n) - \min({data}_{FI})}{\max({data}_{FI}) - \min({data}_{FI})}$. To calculate the maximum \[$\max({data}_{FI})$\] and minimum \[$\min({data}_{FI})$\], all data sets were used. The resulting clusters (each point represents one B-scan) were visualized in a scatter plot (5-ALA-positive/negative and infiltration zone). For the statistical analysis, mean values of attenuation and FI data were calculated for each of the 12 samples. Mann--Whitney U tests with Bonferroni correction were performed to test for the equality of the distributions in attenuation and fluorescence data using a significance level of $p < 0.01$.

![The data processing pipeline. First, OCM and FI images are acquired. Attenuation maps are generated from the OCM data. Attenuation coefficients are averaged in a chosen region of interest. The results from the attenuation analysis are then compared in a scatter plot with their respective averaged FI values.](JBO-024-066010-g002){#f2}

Further cell counting in OCM volumes was performed. Subvolumes consisting of regions of interest of $120 \times 200 \times 20\text{  }{\mu m}^{3}$ were evaluated. For each volume three times the same area was evaluated. The cells, appearing as hyposcattering regions in the intensity volumes, were manually annotated using ITK-Snap.[@r70] The binary output files were then used to perform automatic cell counting using the three-dimensional (3-D) objects counter tool in Fiji.

3. Results {#sec3}
==========

3.1. Curcumin Phantom Measurements {#sec3.1}
----------------------------------

A curcumin phantom was imaged to validate the performance of the system. The excitation and emission spectra of curcumin are shown in [Fig. 3(a)](#f3){ref-type="fig"} along with the filters used. In the fluorescence image \[[Fig. 3(b)](#f3){ref-type="fig"}\], a clear contrast between pure paper and the mounting medium mixed with curcumin is visible. A representative intensity B-scan image and the intensity averaged OCM en-face projection over $50\text{  }\mu m$ are shown in [Figs. 3(c)](#f3){ref-type="fig"} and [3(d)](#f3){ref-type="fig"}, respectively. Note that it is challenging to distinguish the curcumin from the paper in the OCM en-face image. [Figure 3(e)](#f3){ref-type="fig"} shows an overlay of the OCM en-face image (red) and the corresponding fluorescence image (green).

![Curcumin phantom imaging with the multimodal setup. (a) Excitation and emission spectra of curcumin. The excitation (blue) and emission (green) filters used in the system are indicated by color bands.[@r71] (b) Fluorescence image of the mounting medium mixed with curcumin on the paper. (c) A corresponding B-scan OCM image taken at the location indicated by a yellow dashed line in image (d). (d) OCM en-face projection over $50\text{  }\mu m$. (e) Overlay of the OCM (red) and the fluorescence image (green). All images are taken with a $20 \times$ magnification objective lens.](JBO-024-066010-g003){#f3}

3.2. Amyloid-Beta Plaque Imaging in Brain Tissue of an Alzheimer's Disease Mouse Model {#sec3.2}
--------------------------------------------------------------------------------------

Curcumin-stained brain sections of a mouse model of AD were imaged with the combined setup ([Fig. 4](#f4){ref-type="fig"}). An immunohistochemical and hematoxylin-stained histology image of an adjacent brain region is shown in [Fig. 4(a)](#f4){ref-type="fig"}. Amyloid-beta plaques appear as brown structures. [Figure 4(b)](#f4){ref-type="fig"} shows an image of a $3\text{-}\mu m$-thick brain section stained with curcumin taken with a commercial fluorescence Olympus microscope. The plaques can be identified as regions with increased fluorescence due to curcumin. A similar region in a $3\text{-}\mu m$-thick brain section was imaged with the OCM/FI setup, and the FI results are shown in [Fig. 4(c)](#f4){ref-type="fig"}. Again, amyloid-beta plaques can be identified as highly fluorescent structures. A $100\text{-}\mu m$-thick brain slice was first imaged with a commercial laser scanning microscope \[[Fig. 4(d)](#f4){ref-type="fig"}\]. A representative OCM B-scan of the vibratome section is shown in [Fig. 4(e)](#f4){ref-type="fig"}. A plaque can be identified as a hyperscattering structure. [Figure 4(f)](#f4){ref-type="fig"} shows an OCM intensity en-face projection over $10\text{  }\mu m$ underneath the tissue surface. A plaque shows up as a highly scattering feature. The corresponding fluorescence image is shown in [Fig. 4(g)](#f4){ref-type="fig"}. The focus was set at the same depth as for the OCM acquisition. Finally, a composite image of OCM (red) and fluorescence (green) image is shown in [Fig. 4(h)](#f4){ref-type="fig"}. The amyloid-beta plaque, which is present in both the OCM and the fluorescence image, can be observed in a yellowish color. Another plaque, which is present in the fluorescence image, is barely visible in the OCM image. The dark spots in the fluorescence image are cells and appear as hyposcattering in the OCM images. [Figure 4(i)](#f4){ref-type="fig"} shows an average en-face projection over the whole $100\text{  }\mu m$ in a slightly bigger area with hyperscattering plaques indicated by yellow arrows.

![Imaging of curcumin-stained brain sections of an AD mouse model. (a) Immunohistochemical and hematoxylin-stained tissue section of a plaque-rich region ($20 \times$ magnification). (b) Fluorescence image of the $3\text{-}\mu m$-thick section imaged with $20 \times$ magnification (Olympus BX51 microscope). (c) FI image taken with the combined OCM/FI setup of a $3\text{-}\mu m$-thick section. (d) The $100\text{-}\mu m$-thick brain section imaged with the laser scanning microscope (LSM 700 Zeiss). (e) Representative OCM intensity B-scan image. (f) OCM en-face projection over $10\text{  }\mu m$ underneath the tissue surface. (g) Corresponding fluorescence image. (h) An overlay of the OCM (red) and the fluorescence image (green). (i) OCM en-face projection over the whole depth range. The thicknesses of the measured tissue slices are indicated in brackets in the right corner of the images. Plaques are marked with yellow arrows in images (f)--(i).](JBO-024-066010-g004){#f4}

3.3. Imaging of 5-ALA Brain Tumor Biopsies {#sec3.3}
------------------------------------------

5-ALA-positive tumor samples retrieved intraoperatively were imaged prior to routine neuropathologic work-up. In [Fig. 5(a)](#f5){ref-type="fig"}, the excitation and emission spectra of 5-ALA are plotted. The emission (red) and excitation (blue) filter spectra are indicated by color bands.[@r72] In [Figs. 5(b)](#f5){ref-type="fig"}--[5(d)](#f5){ref-type="fig"}, histological images are shown for a 5-ALA-negative area, an infiltration zone, and a 5-ALA-positive area. Tumor area and infiltration zone can be distinguished by the densities of malignant cells. In the infiltration zone, areas of physiological brain tissue with infiltrating malignant cells (indicated by green arrows) can be observed. An average en-face projection over $20\text{  }\mu m$ and a representative B-scan image of a 5-ALA-positive area are shown in [Figs. 5(e)](#f5){ref-type="fig"} and [5(f)](#f5){ref-type="fig"}, respectively. The averaged attenuation map shows lower values in the left lower corner \[[Fig. 5(g)](#f5){ref-type="fig"}\]. The combined OCM (blue) and fluorescence image (red) in [Fig. 5(h)](#f5){ref-type="fig"}, in the same area, shows a stronger fluorescence signal indicating a higher density of malignant cells.[@r73] An average en-face projection over $20\text{  }\mu m$ and a representative B-scan image of a 5-ALA-negative area are shown in [Figs. 5(i)](#f5){ref-type="fig"} and [5(j)](#f5){ref-type="fig"}, respectively. Compared to 5-ALA-positive tissue, the tissue morphology is more homogeneous and the intensity in the OCM image is increased.

![Imaging of 5-ALA-positive and -negative human brain biopsies. (a) Excitation and emission spectra of 5-ALA .[@r72] (b--d) Histology of a control region, an infiltration zone, and a core tumor zone. (e) Intensity en-face OCM projection over $20\text{  }\mu m$ in a 5-ALA-positive area. (f) Representative B-scan image of (e). (g) Average attenuation map over $20\text{  }\mu m$ in a 5-ALA-positive area. (h) OCM en-face projection (blue) overlaid with the FI image (red). The dotted line in panels (e) and (g) outlines the hyperfluorescent region in panel (h). (i) Intensity en-face OCM projection over $20\text{  }\mu m$ in a 5-ALA-negative area. (j) Representative B-scan image of (i).](JBO-024-066010-g005){#f5}

Cell counting was conducted in three OCM data sets, three times each for one tumor area, a nontumorous area, and an infiltration zone. As shown in [Fig. 6(a)](#f6){ref-type="fig"}, the cell count in the 5-ALA-positive area and the infiltration zone was 139% and 15% higher than in 5-ALA-negative tissue, respectively. Attenuation maps for all measured OCM volumes were calculated. [Figure 6(b)](#f6){ref-type="fig"} shows the averaged attenuation coefficients over B-scans plotted over the averaged intensity values retrieved from the fluorescence images. For the statistical evaluation mean values for all 12 data sets were evaluated. The 5-ALA-positive tissue exhibits lower attenuation coefficients and higher fluorescence values when compared to 5-ALA-negative area. The mean attenuation values in the infiltration zone compared to the 5-ALA-negative area showed a trend to be lower but no significance was found ($p = 0.014$). The mean attenuation values in the infiltration zone compared to the 5-ALA-positive area showed a trend to be higher but no significance was found ($p = 0.15$). All other results were statistically significant ([Table 2](#t002){ref-type="table"}) with a $p$-value of $< 0.01$. The mean values of the clusters which were tested for different distributions are indicated by the color bars in [Fig. 6(b)](#f6){ref-type="fig"}.

###### 

The detailed information of the Mann--Whitney U results, testing if the clusters originated from different continuous distributions. The first column indicates the tests which were conducted, F(5-ALA−) corresponds to the 5-ALA-negative area, F(5-ALA +) to the infiltration zone, and F(5-ALA ++) to the 5-ALA-positive area, and $\mu_{a}$ is indicating the calculated mean attenuation values. (\*Significance level $p < 0.01$.)

  Mann--Whitney U test                            Significance
  ----------------------------------------------- --------------
  F(5-ALA ++) versus F(5-ALA +)                   $p < 0.01$
  F(5-ALA ++) versus F(5-ALA −)                   $p < 0.01$
  F(5-ALA +) versus F(5-ALA −)                    $p < 0.01$
  $\mu_{a}$(5-ALA ++) versus $\mu_{a}$(5-ALA +)   $p = 0.15$
  $\mu_{a}$(5-ALA ++) versus $\mu_{a}$(5-ALA −)   $p < 0.01$
  $\mu_{a}$(5-ALA +) versus $\mu_{a}$(5-ALA −)    $p < 0.014$

![Evaluation of OCM and FI data 5-ALA-positive and -negative human brain biopsies. (a) Cell counting results from the OCM volumes. (b) The averaged attenuation coefficients (each point represents one B-scan) were plotted over the averaged intensity values retrieved from the FI images. (\*Significance level $p < 0.01$.) The mean value of each data set is indicated by a yellow dot.](JBO-024-066010-g006){#f6}

4. Discussion {#sec4}
=============

We developed a combined visible light OCM and FI setup. Our multimodal system presents a compact and simple design to consecutively acquire OCM and FI data by using a single light source for both modalities in comparison to previously reported work.[@r15]^,^[@r18]^,^[@r19]^,^[@r22][@r23]^--^[@r24]^,^[@r26][@r27][@r28][@r29][@r30][@r31][@r32]^--^[@r33] Switching from OCM imaging to FI is achieved by simply flipping two mirrors in the setup. Another advantage of our setup is that it has the possibility to detect a variety of standard fluorescence dyes as the light source spectrum covers the whole visible range. To image specific fluorescent dyes, the system can be equipped with different filter cubes that are readily available for commercial fluorescence microscopes. In order to further improve the system and to enable fast switching between different dyes, it might be an option to assemble multiple filter cubes that could then be integrated in an automated wheel or stage for quick exchange. At the same time, using the broad visible spectrum for OCM, an axial resolution of $0.88\text{  }\mu m$ in brain tissue was achieved, which enabled imaging on a cellular level. When investigating amyloid-beta plaques, which are in the range of 10 to $200\text{  }\mu m$, a high resolution is crucial.[@r74]

Further technological improvements of the OCM/FI setup could enable dynamic focusing and 3-D FI. While focusing was done manually in the current implementation, setting the focus for FI and OCM imaging in the future could be done using an automatic $z$-stage. The implementation of such a stage would also enable the acquisition of confocal image stacks of 3-D FI data. For now, the focus was set at the same position as the OCM image, at the top of the surface of the tissue. The penetration depth into brain tissue using visible light OCM was limited to $\sim 100\text{  }\mu m$. Investigating optically cleared tissue would increase the penetration depth, as has been shown in our previous work.[@r6] Further, to achieve good FI results, a flat surface would be optimal. Imaging a curved tissue surface was challenging as the signal at the image borders is reduced and fewer structures can be identified. This effect can for example be observed in [Figs. 4(f)](#f4){ref-type="fig"}--[4(h)](#f4){ref-type="fig"}. One possibility to overcome this issue could be to acquire multiple stacks and fuse them to increase the image quality and suppress speckle noise.[@r75]

A commercial $20 \times$ objective lens was used for imaging. Using higher numerical aperture (NA) would result in a better fluorescence signal. In future, objective lenses with even higher NA will be used to investigate smaller anatomical features with a better fluorescent response.

For the data acquisition, first the FI image and then OCM volumes were acquired to prevent bleaching. For all measurements, the same power, pinhole settings, and objective lens were used. The focus was always set at the tissue surface. Furthermore, imaging was performed in a darkened room. The measured FI intensity is also dependent on the biopsy shape and the autofluorescence.[@r76] As a next step calculating a relative or quantitative fluorescence intensity will be investigated, following, for example, Valdés et al.[@r77] For that purpose, a fluorescence phantom is needed as a reference to achieve correct relative intensity values.

Two application possibilities of the setup in the field of neuroimaging were presented. First, brain tissue slices of an AD mouse model stained with curcumin were imaged. The investigations revealed that with the same light source amyloid-beta plaques can be specifically identified using FI, and the morphology of the brain tissue, including anatomical features, can be investigated by OCM. The plaques were identified in the OCM images as highly scattering structures and in the FI images as highly fluorescent spots. The additional fluorescence channel confirmed that the highly scattering structures observed with OCM are amyloid-beta plaques. The results were in good agreement with literature and histology.[@r5]^,^[@r7]^,^[@r25] To improve the sensitivity to detect amyloid-beta plaques, thioflavin-S-stained brain tissue could be investigated. It was shown that thioflavin-S may be a more suitable fluorescence marker for the detection of amyloid-beta plaques compared to curcumin.[@r46] As a next step, the FI channel could be utilized to investigate tau accumulations, which could add additional insights in the mechanisms of the disease.

Second, 5-ALA-positive and -negative human brain biopsies from tumor surgeries were investigated prior to neuropathologic work-up. The 5-ALA-positive regions in the samples were visualized by FI and morphological OCM information of the tissue was acquired with minimal delay. For all data sets, attenuation maps were calculated and analyzed. The attenuation in the 5-ALA-positive areas was significantly lower than 5-ALA-negative brain areas, and the fluorescence signal was significantly higher. Due to autofluorescence of the tissue, in some cases \[see [Fig. 6(b)](#f6){ref-type="fig"}\], it was hard to distinguish the negative and infiltration zone. In these cases, the multimodal approach using fluorescence and attenuation values may provide better contrast. Using in total 12 biopsies, a preliminary analysis is presented in this article; however, a greater sample size will be needed to achieve a more reliable statistical conclusion. Still, the attenuation values and their decrease in tumorous tissue were in good agreement with the literature.[@r12]^,^[@r78]^,^[@r79] Kut et al. described that tumors infiltrate into white matter, breaking down myelin and therefore decreasing its expression. This ultimately leads to a lower attenuation.[@r12] OCM-based cell counting results showed an increase of 139% from 5-ALA-negative to 5-ALA-positive tissues and 15% increase in the infiltration zone. Our results showed that malignant tissue exhibits a higher cellularity compared to nontumorous brain tissue.[@r80] These data were in agreement with histology. The cell counting results will further be compared to cellularity maps generated from histological data of the same region. OCM findings identifying malignant areas within brain biopsies were further correlated to histopathological routine analysis and were in good agreement. For the future, more samples will be imaged with our multimodal system to evaluate sensitivity and specificity of using OCM/FI for tumor intraoperative assessment. The focus will also lie in differentiating low and high grade glioma samples using the multimodal approach.

5. Conclusion {#sec5}
=============

A multimodal visible light OCM and FI setup was introduced. A supercontinuum laser emitting a broad visible spectrum enabled to achieve submicrometer axial resolution for OCM imaging and by simply flipping two mirrors, the system can be changed from OCM to FI mode using the same light source. The performance was characterized by imaging fluorescent microbeads and a curcumin fluorescence phantom. Two applications of the multimodal approach in the field of neuroimaging were demonstrated. First, curcumin-stained brain slices of a mouse model of AD were imaged. Amyloid-beta plaques, one hallmark of AD, were specifically identified using FI. Consecutively, the brain morphology was investigated in 3-D using OCM, and by FI, the OCM results could be validated. Second, 5-ALA-positive and -negative brain biopsies were imaged. Average attenuation coefficients and fluorescence intensity values showed significances differences between 5-ALA-positive and -negative brain tissue. Cell counting was performed in the OCM data showing a typical increase in cellularity in malignant tissue. This multimodal approach offers the possibility to investigate microscopic, 3-D features using OCM and at the same time gain tissue-specific contrast by FI. Using OCM in combination with FI may therefore be a versatile and powerful tool for many applications in the field of neuroscience.
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